Abl oncogene bypasses normal regulation of Jak/STAT activation

Related Experiment Video

Updated: Aug 20, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

André Limnander1, Paul B Rothman

  • 1Integrated Program in Cellular, Molecular and Biophysical Studies, Columbia University College of Physicians and Surgeons, New York, New York USA.

Cell Cycle (Georgetown, Tex.)
|December 22, 2004
PubMed

Insights

The v-Abl oncogene constitutively activates Jak-Stat signaling by modifying SOCS-1, a protein that normally inhibits this pathway. This disruption prevents the degradation of Jak kinases, promoting cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Normal cells tightly regulate proliferative signaling pathways.
  • Cancer cells often bypass negative regulatory mechanisms for constitutive pathway activation.
  • The v-Abl oncogene is known to activate signaling pathways involved in cell proliferation.

Purpose of the Study:

  • To identify the mechanism by which the v-Abl oncogene bypasses negative regulation.
  • To elucidate how v-Abl achieves constitutive activation of Jak-Stat signaling.
  • To understand the role of SOCS-1 in v-Abl-mediated oncogenesis.

Main Methods:

  • Investigated the interaction between v-Abl and SOCS-1.
  • Analyzed post-translational modifications of SOCS-1.
  • Examined the effect of these modifications on SOCS-1's interaction with the proteasome.
  • Assessed the degradation of Jak kinases.

Main Results:

  • Identified a mechanism where v-Abl modifies SOCS-1.
  • These modifications disrupt SOCS-1's proteasomal degradation pathway.
  • This disruption prevents the degradation of activated Jak kinases.
  • Constitutive activation of Jak-Stat signaling is achieved.

Conclusions:

  • The v-Abl oncogene utilizes a novel mechanism to bypass SOCS-1-mediated negative regulation.
  • Post-translational modification of SOCS-1 is key to constitutive Jak-Stat activation by v-Abl.
  • Findings provide insights into v-Abl oncogenesis and SOCS protein regulation.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...